Rituximab with low-dose mycophenolate for lupus nephritis in children
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 18 years old.
- You have been diagnosed with systemic lupus erythematosus and a specific type of kidney inflammation called proliferative lupus nephritis (type III or IV, which may also have type V).
- Your lupus is active, with high protein in your urine (at least 25 mg/kg in a 24-hour test or a urine protein/creatinine ratio of 1.0 mg/mg or higher).
- Your kidney function is fairly good, with an estimated GFR of 60 mL/min or more.
- You have not previously received cyclophosphamide or rituximab as an induction treatment.
- You and your guardian (if you are over 8) agree to the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.